Donald J Trump (R) Buys Shares of Boston Scientific
The former president acquired shares valued between $100,001 and $250,000.
Financial Disclosure Report
United States Congress • Office of Public Records • Washington, DC
Filer Information
- Name:
- Donald J Trump (R)
- Status:
- Member
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 1, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Boston Scientific Corporation ($BSX) | Buy | May 22, 2026 | $100,001 - $250,000 |
Key Points
- Donald J Trump purchased shares of Boston Scientific between $100,001 and $250,000 on May 22, 2026.
- Shares of BSX traded near $42.6 on Wednesday with a market cap of approximately $63.4 billion.
- Analysts maintain a 'buy' rating on BSX with price targets ranging from $64 to $74.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Donald J Trump, the former president and a prominent figure in the Republican party, bought shares of Boston Scientific Corporation (NYSE:BSX) on May 22, 2026. The purchase was valued between $100,001 and $250,000, according to a disclosure under the STOCK Act. This transaction was reported on July 1, 2026.
Donald J Trump vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Boston Scientific Corporation Stock Down 8.6%
Shares of NYSE:BSX traded near $42.6 as of Wednesday. Boston Scientific, a leading player in the healthcare sector, has a market capitalization of about $63.4 billion. The company boasts a P/E ratio of 17.9 and a forward P/E of 11.5, indicating expectations of future earnings growth. With a beta of 0.559, the stock is less volatile compared to the market. The 52-week range for the stock is between $42.25 and $109.5, with moving averages of $52.68 (50-day) and $79.31 (200-day).
$BSX stock price
Daily closing prices, year to date. Not investment advice.
Other Institutional Activity in Boston Scientific
Several major institutional investors have also adjusted their stakes in Boston Scientific. BlackRock, Inc. reduced its holdings by about 4.2 million shares, bringing its total to approximately 131.8 million shares valued at $8.27 billion, a 3.1% decrease. Vanguard Capital Management LLC opened a new position with over 96.4 million shares, valued at roughly $6.05 billion. FMR LLC significantly cut its stake by 23.8%, now holding about 74.2 million shares worth $4.66 billion. State Street Corp added 2.1 million shares, totaling nearly 68 million shares valued at $4.27 billion, representing a 3.3% increase. JPMorgan Chase & Co grew its holdings by 7.98 million shares, showing a 31.4% increase, ending with 33.35 million shares worth $2.1 billion.
Recent Earnings
Boston Scientific reported revenue of $20.61 billion, reflecting a growth of 11.6%. The company achieved a net margin of 17.3% and a return on equity of 14.7%. Earnings per share stood at $2.39. The next earnings release is scheduled for July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Recent insider transactions at Boston Scientific include several purchases. David Habiger acquired 2,250 shares at an average price of $55.92 on May 20, 2026. Edward Ludwig bought 3,580 shares at $56.68, and Cheryl Pegus purchased 1,770 shares at $56.49 on the same day. These transactions indicate continued insider interest in the company's stock.
Analysts Set New Price Targets
Analysts continue to show optimism for Boston Scientific. On June 25, 2026, Stifel maintained a 'buy' rating with a price target of $65. Jefferies also maintained a 'buy' rating on June 24, 2026, with a target of $67. BTIG reiterated their 'buy' stance with a $65 target on June 16, 2026. The consensus among 29 analysts is a 'buy' recommendation, with a mean price target of $75.
About Boston Scientific
Boston Scientific Corporation is a global medical device company headquartered in Marlborough, Massachusetts. It develops, manufactures, and markets a range of medical devices for interventional medical specialties. The company operates through its MedSurg and Cardiovascular segments, offering products for gastrointestinal, urological, and cardiovascular treatments, among others. Led by CEO Michael F. Mahoney, Boston Scientific employs approximately 59,000 people worldwide.
Bottom Line
Donald J Trump's recent purchase of Boston Scientific shares highlights ongoing interest in the medical device company. As analysts continue to project a positive outlook, with numerous 'buy' ratings and high price targets, Boston Scientific remains a focal point for investors. This transaction, reported well after the fact, is a reminder of the backward-looking nature of STOCK Act disclosures.
Get Boston Scientific Corporation alerts
New 13F filings, insider trades, and analyst moves on $BSX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.